Stay updated on Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page
- Check7 days agoChange DetectedSite version updated from v3.4.3 to v3.5.0. The study information remains unchanged.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check29 days agoNo Change Detected
- Check44 days agoChange DetectedMinor revision note updated from v3.4.1 to v3.4.2; no user-facing content or functionality appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedAdded Sarah Cannon Research Institute / Tennessee Oncology in Nashville, TN as a recruitment site; total study locations updated from 127 to 128.SummaryDifference0.2%

- Check58 days agoChange DetectedNo significant additions or deletions were detected; the page content and structure appear unchanged between screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedUI updates add a Show/Hide glossary control and No FEAR Act data capitalization tweaks, along with Last Update fields and a new Revision: v3.4.0. These changes do not affect core study details or results.SummaryDifference0.2%

Stay in the know with updates to Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.